Roche launches BAP1 test: what it means for Roche Holding stock
Published on 10/28/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDiagnostic expansion and market context
- Roche launched the VENTANA BAP1 test globally on October 28, 2026.
- The assay is registered in the United States and approved under European rules as a Class C device.
- Roche Holding stock was trading at EUR 428.75 at Lang & Schwarz on October 28, 2026.
Roche Holding (ISIN CH1499059983) launched the VENTANA BAP1 test globally on October 28, 2026, expanding its cancer diagnostics portfolio for mesothelioma. The company said the automated assay helps distinguish malignant mesothelioma from lung, breast and stomach cancers and from benign tissue growth, according to Roche.
What the new test adds
The BAP1 test is designed for automated immunohistochemistry testing and detects the loss of BAP1 expression, a marker associated with malignant mesothelioma. Roche said the assay is registered as a Class I in-vitro diagnostic with the U.S. Food and Drug Administration, has received approval under the European In Vitro Diagnostic Regulation as a Class C device, and is available globally.
The launch adds another tool to Roche's expanding lung cancer and mesothelioma portfolio. The company said BAP1 works alongside the recently launched VENTANA MTAP and Claudin-4 tests, helping pathologists preserve limited tissue samples for molecular sequencing and precision medicine testing.
Why diagnosis matters for patients
Roche's release said most mesothelioma patients are diagnosed late, when median overall survival is 12 to 18 months. More than 80 percent of cases are found in the pleural cavity, according to the same Roche release.
Recent Roche operating signals
On October 22, 2026, Roche reported that group sales rose 6 percent at constant exchange rates to CHF 46.5 billion in the first nine months of 2026 and confirmed its full-year outlook. The update also described third-quarter sales growth of 7 percent at constant exchange rates, giving the diagnostic launch a broader operating backdrop.
For investors, the commercial effect of BAP1 will depend on adoption across pathology laboratories rather than on a financial figure disclosed with the launch. Roche provided no sales forecast or revenue contribution for the assay in the release.
Stock price on October 28
Roche Holding stock was trading at EUR 428.75 at Lang & Schwarz on October 28, 2026 at 10:37 a.m. Berlin time. The quote provides the market snapshot while the new product launch supplies the fresh company-specific catalyst.
The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.
Roche Holding facts
- Company: Roche Holding AG
- ISIN: CH1499059983
- Ticker: RO
- Primary exchange: SIX
- Price Lang & Schwarz (as of October 28, 2026, 10:37 a.m. Berlin time): EUR 428.75
- Sector / Industry: Healthcare, pharmaceuticals and diagnostics
Market context: Market report SMI.
